$ARQT News

FDA Accepts Supplemental New Drug Application For Arcutis Biotherapeutics' ZORYVE Cream 0.05%

Reported Earlier, Arcutis Expands ZORYVE Label With FDA Approval For Once-Daily Steroid-Free Plaque Psoriasis Treatment In Young Children

Arcutis Biotherapeutics Inc (NASDAQ:ARQT): A GARP Growth Play at a Reasonable Price

Is Arcutis (ARQT) Using Genital Psoriasis Education to Quietly Reshape Its Dermatology Strategy?

Arcutis Biotherapeutics Touts ZORYVE Growth, FDA Catalysts and Cash-Flow Positive Status

Arcutis Biotherapeutics, Inc. (ARQT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology

UPDATE: Arcutis Highlights New Expert Guidance For Diagnosing And Managing Genital Psoriasis Across All Age Groups

Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference

Arcutis Biotherapeutics: The Dermatology Platform Is Starting To Compound

Arcutis Biotherapeutics (ARQT) Is Down 11.0% After Strong Q1 And sNDA For ZORYVE Expansion

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Biotherapeutics, Inc. Q1 2026 Earnings Call Summary

Needham Reiterates Buy on Arcutis Biotherapeutics, Maintains $36 Price Target

Arcutis Biotherapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation

Arcutis Biotherapeutics, Inc. (ARQT) Q1 2026 Earnings Call Transcript

Arcutis Biotherapeutics Q1 Earnings Call Highlights

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Beats Revenue Estimates

Arcutis Biotherapeutics (NASDAQ:ARQT) Beats Q1 Revenue Estimates but Posts Wider-Than-Expected Loss; Shares Slide